Follicular dendritic cell sarcoma (FDCS) is a rare tumor, and it is even rarer for FDCS, to affect liver. FDCS is recognized as a distinct entity by the World Health Organization (WHO). Diagnosis is usually post resection and based on typical immunohistochemical stains. Resection with histologic negative margins is proposed, as a mainstay of therapy. We report a 63-year-old woman with large FDCS of the liver, managed with right hemihepatectomy. She remains disease-free at 48 months. 
INTRODUCTION
Follicular dendritic cell sarcoma (FDCS) is a slowgrowing low grade sarcomatous tumor, of mesenchymal dendritic cell origin.
1 It is a rare disorder, and accounts for 0.4% of all soft tissue sarcomas with peak incidence in the fifth decade of life, and equal gender predisposition. 2 Liver and spleen involvement are even rarer, with only a handful of case reports. 3 Due to slow growth and absence of pain, it is common for FDCS to present with large size, and symptoms due to size.
1,3 CASE
A 63-year-old woman was presented to the hospital with fever and lethargy. She had no significant medical history. On examination, a firm non-tender mass extending 5 cm below the right costal margin was palpable.
There were no stigmata of chronic liver disease. Routine hematology and serum biochemistry was unremarkable.
Ultrasound of the abdomen showed a heterogeneous hypodense mass measuring 13.4×12.6×10.3 cm, in the right lobe of the liver with vascularity, and compressing the gall bladder. Hepatitis B and C viral serology were negative. Alpha-fetoprotein, carcinoembryonic antigen, and carbohydrate antigen 19-9 were normal. Computerized tomography (CT) scan of the thorax-abdomen-pelvis confirmed sonography findings. Also, the mass was exophytic, centered at the gallbladder fossa, and had areas of hypervascularity and necrosis within it (Fig. 1A) . The mass appeared to displace portal inflow medially ( A large retrospective review suggested curative surgery as standard treatment, with no adjuvant chemo radiation.
Post-operative radiotherapy is currently advocated, for lesions incompletely resected. 8 Some reports also claim on possible metastatic potential of these tumors. 7 Our patient presented with a large palpable mass in the right upper abdomen, and did not show evidence of metastatic disease.
Hence, surgical resection was planned. Pre-operatively we did not suspect diagnosis of FDCS, and we do not advocate liver biopsy for tissue diagnosis, as it doesn't alter the management plan i.e. surgical resection; and also poses risk of bleeding and tumor seeding along the biopsy track.
FDCS is a rare case of solid liver lesion, and diagnosis is usually after resection. In patients with histological negative margins, surveillance is adequate. However, it is essential to be vigilant about FDCS as a distinct entity, due risk of recurrence, or metastases. FDCS are shown to be hypermetabolic and observed as avid spots on positron emission tomography scan. 9 Rarity of FDCS to affect extranodal solid organs, serves as an obligation to report experience of single cases, as this adds to the understanding of natural history and behavior of these rare neoplasms.
